卡瑞利珠单抗联合安罗替尼对晚期食管癌患者疗效及淋巴细胞亚群的影响

Therapeutic effect and lymphocyte subsets of combination therapy with Carolizumab and Anlotinib in advanced esophageal cancer patients

目的观察和分析晚期食管癌患者联合应用卡瑞丽珠单抗及安罗替尼的临床疗效以及对淋巴细胞亚群产生的影响。方法将自2020年1月至2023年3月进行治疗的晚期食管癌患者116例分为2组,均应用紫衫醇和紫杉醇^(+)顺铂(TP)方案,采用随机数字表法为分组工具,对照组联合应用卡瑞丽珠单抗注射液治疗,观察组联合应用卡瑞丽珠单抗及安罗替尼治疗,比较近期临床疗效、预后情况以及术后并发症情况。结果观察组患者客观缓解率及临床总有效率均高于对照组(P<0.05)。2组治疗前CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)及NK细胞水平差异无统计学意义(P>0.05),治疗后观察组CD4^(+)、CD4^(+)/CD8^(+)、NK细胞水平均高于对照组,CD8^(+)低于对照组(P<0.05)。治疗前2组鳞状细胞瘤相关抗原(SCC-Ag)、高迁移率蛋白B1(HMGB1)、癌胚抗原(CEA)水平差异无统计学意义(P>0.05),治疗后观察组各项血清肿瘤标志物水平均较对照组低(P<0.05)。观察组Ⅲ级声音嘶哑率、Ⅲ级肺炎率及Ⅲ级气胸率高于对照组(P<0.05)。结论晚期食管癌患者联合应用卡瑞丽珠单抗、安罗替尼对于促进近期临床疗效提升有重要意义,能够促进肿瘤标志物水平降低并可有效减轻对免疫力造成的影响。

Objective To observe and analyze the clinical efficacy and impact on lymphocyte subsets of patients with advanced esophageal cancer treated with a combination of Carolizumab and Anlotinib.Methods A totol of 116 patients with advanced esophageal cancer who underwent treatment from January 2020 to March 2023 were divided into two groups,both using the TP regimen.The random number table method was used as the grouping tool.The control group was treated with a combination of Carrelizumab injection,while the observation group was treated with a combination of Carrelizumab and Anlotinib.The recent clinical efficacy,prognosis,and postoperative complications were compared.Results Compared with the control group,the objective remission rate,and the total clinical efficacy rate in the observation group were much higher(P<0.05).There was no significant difference in CD4^(+),CD8^(+),CD4^(+)/CD8^(+),and NK cell levels between the two groups before treatment(P>0.05).After treatment,the CD4^(+),CD4^(+)/CD8^(+),and NK cell levels in the observation group were much higher,while CD8^(+)was lower than those in the control group(P<0.05).Before treatment,there was no significant difference in the levels of squamous cell carcinoma-related antigen(SCC-Ag),high mobility group box 1(HMGB1),and carcinoma embryonic antigen(CEA)between the two groups(P>0.05).After treatment,the levels of various serum tumor markers in the observation group were much lower(P<0.05).The observation group had higher rates of grade III hoarseness,grade III pneumonia,and grade III pneumothorax compared to the control group(P<0.05).Conclusion The combined use of Karelizumab and Anlotinib in advanced esophageal cancer patients can significantly improve short-term clinical efficacy,reduce serum tumor marker levels,and effectively alleviate the impact on immunity.